Literature DB >> 11510126

Protective effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats.

S Attri1, S V Rana, K Vaiphie, R Katyal, C P Sodhi, S Kanwar, K Singh.   

Abstract

Status of oxidative/antioxidative profile was the mechanistic approach to inumerate the nature of protection by N-acetylcysteine (NAC) in isoniazid (INH) exposed experimental animals. Analysis of lipid peroxidation, thiol levels, cytochrome P450, superoxide dismutase (SOD), catalase, glutathione peroxidase, reductase and transferase were estimated in liver along with the body and liver weight of animals and histological observations. Isoniazid exposure to animals resulted in no change in body and liver weights. Thiols, lipid peroxidation, catalase, SOD glutathione peroxidase, reductase, transferase and cytochrome P450 levels were altered with INH exposure. Supplementation of NAC with INH protected the animals against hepatotoxic reactions by minimizing the free radical induced tissue injury and overall maintenance of the endogenous scavengers of free radicals.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11510126

Source DB:  PubMed          Journal:  Indian J Exp Biol        ISSN： 0019-5189            Impact factor:   0.818


  10 in total

Review 1.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

2.  Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China.

Authors:  Na Xu; Jing Xiang Yang; Jian Yang
Journal:  Eur J Hosp Pharm       Date:  2020-09-28

3.  A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.

Authors:  Hoda A Makhlouf; Ahmed Helmy; Ehab Fawzy; Madiha El-Attar; Hebat Alla G Rashed
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

4.  N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease.

Authors:  Manouchehr Khoshbaten; Akbar Aliasgarzadeh; Koorosh Masnadi; Mohammad K Tarzamani; Sara Farhang; Hosain Babaei; Javad Kiani; Maryam Zaare; Farzad Najafipoor
Journal:  Hepat Mon       Date:  2010-03-01       Impact factor: 0.660

5.  A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.

Authors:  Chote Luangchosiri; Ammarin Thakkinstian; Sermsiri Chitphuk; Wasana Stitchantrakul; Supanna Petraksa; Abhasnee Sobhonslidsuk
Journal:  BMC Complement Altern Med       Date:  2015-09-23       Impact factor: 3.659

6.  Expression Profile of Markers of Apoptosis, Injury and Oxidative Stress in Human Lung Epithelium Cells-A5449 Receiving Chronic Exposure of Potential Anti-Tubercular Drug-trans-Cyclohexane-1, 4-Diamine Derivative-"9u".

Authors:  Ekta Kapoor; Vinay Tripathi; Vivek Kumar; Vijay Juyal; Sunita Bhagat; Veerma Ram
Journal:  Toxicol Int       Date:  2014-05

Review 7.  Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview.

Authors:  Divya Singh; William C Cho; Ghanshyam Upadhyay
Journal:  Front Physiol       Date:  2016-01-26       Impact factor: 4.566

8.  N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions.

Authors:  Eduardo P Amaral; Elisabete L Conceição; Diego L Costa; Michael S Rocha; Jamocyr M Marinho; Marcelo Cordeiro-Santos; Maria Regina D'Império-Lima; Theolis Barbosa; Alan Sher; Bruno B Andrade
Journal:  BMC Microbiol       Date:  2016-10-28       Impact factor: 3.605

9.  Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals.

Authors:  Sude Eminzade; Fikriye Uraz; Fikret V Izzettin
Journal:  Nutr Metab (Lond)       Date:  2008-07-05       Impact factor: 4.169

10.  The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against Mycobacterium tuberculosis.

Authors:  Garrett Teskey; Ruoqiong Cao; Hicret Islamoglu; Albert Medina; Chaya Prasad; Ramaa Prasad; Airani Sathananthan; Marcel Fraix; Selvakumar Subbian; Li Zhong; Vishwanath Venketaraman
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.